计算溶液所需的质量、体积或浓度。
| 活性类型 | 活性值-log(M) | 作用机制 | 期刊 | 参考文献(PubMed IDs) |
|---|
| 货号 (SKU) | 包装规格 | 是否现货 | 价格 | 数量 |
|---|---|---|---|---|
| T129709-5mg |
5mg |
现货 ![]() |
| |
| T129709-10mg |
10mg |
现货 ![]() |
| |
| T129709-25mg |
25mg |
现货 ![]() |
| |
| T129709-50mg |
50mg |
现货 ![]() |
| |
| T129709-100mg |
100mg |
现货 ![]() |
|
| 别名 | N-(4-(1,1,1,3,3,3-六氟-2-羟基丙-2-基)苯基)-N-(2,2,2-三氟乙基)苯磺酰胺 |
|---|---|
| 英文别名 | T-0901317 | T 0901317 | N-(4-(1,1,1,3,3,3-Hexafluoro-2-hydroxypropan-2-yl)phenyl)-N-(2,2,2-trifluoroethyl)benzenesulfonamide |
| 规格或纯度 | Moligand™, ≥98% |
| 英文名称 | T0901317 |
| 生化机理 | T 0901317 是一种细胞渗透性非甾醇苯磺酰胺化合物,是一种高选择性的强效肝 X 受体 (LXR) 激动剂(对 LXRα 的 EC50 为 20 nM)。据报道,T 0901317 可诱导脂肪酸生物合成相关基因的表达,提高血清高密度脂蛋白胆固醇和甘油三酯的水平。增加与胆固醇外流调节和高密度脂蛋白代谢相关的 ABCA1 表达。增加肌肉中 PPAR-δ 的表达。在体内显示抗致畸作用。 |
| 储存温度 | -20°C储存 |
| 运输条件 | 超低温冰袋运输 |
| 作用类型 | 激动剂 |
| 作用机制 | 肝 X 受体-α的激动剂;肝 X 受体-β的激动剂;RAR 相关孤儿受体-α的激动剂;RAR 相关孤儿受体-γ的激动剂 |
| 备注 | 如果有可能,您尽量在使用的当天配置溶液,并在当天使用完它。但是,如果您需要预先配制储备溶液,我们建议您将溶液等份保存在-20°C的密封小瓶中。通常,它们最多可以使用一个月。在使用前和打开样品瓶之前,我们建议您让您的产品在室温下平衡至少1小时。需要更多关于溶解度,用法和处理的建议吗?请访问我们的常见问题(FAQ)页面以获取更多详细信息。 |
| 产品介绍 |
T0901317是一个强的和选择性的LXR和FXR激动剂,EC50分别是50 nM和5 μM,能够抑制核里的NF/κB。A cell-permeable, nonsterol compound that acts as a highly potent LXR activator T0901317 is a potent and selective agonist for both LXR and FXR, with EC50 of ~50 nM and 5 μM, respectively. |
| 作用机制 | Action Type | target ID | Target Name | Target Type | Target Organism | Binding Site Name | 参考文献 |
|---|
| 分子类型 | 小分子 |
|---|---|
| IUPAC Name | N-[4-(1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2-yl)phenyl]-N-(2,2,2-trifluoroethyl)benzenesulfonamide |
| INCHI | InChI=1S/C17H12F9NO3S/c18-14(19,20)10-27(31(29,30)13-4-2-1-3-5-13)12-8-6-11(7-9-12)15(28,16(21,22)23)17(24,25)26/h1-9,28H,10H2 |
| InChi Key | SGIWFELWJPNFDH-UHFFFAOYSA-N |
| Canonical SMILES | C1=CC=C(C=C1)S(=O)(=O)N(CC(F)(F)F)C2=CC=C(C=C2)C(C(F)(F)F)(C(F)(F)F)O |
| Isomeric SMILES | C1=CC=C(C=C1)S(=O)(=O)N(CC(F)(F)F)C2=CC=C(C=C2)C(C(F)(F)F)(C(F)(F)F)O |
| 关联CAS | 293754-55-9 |
| PubChem CID | 447912 |
| MeSH Entry Terms | N-(2,2,2-Trifluoroethyl)-N-(4-(2,2,2-trifluoro-1- hydroxy-1-trifluoromethylethyl)phenyl)benzenesulfonamide;N-(4-(1,1,1,3,3,3-hexafluoro-2-hydroxy-propan-2-yl)phenyl)-N-(2,2,2-trifluoroethyl)benzenesulfonamide;N-(4-(1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2 |
| 分子量 | 481.33 |
| 溶解性 | DMSO 96 mg/mL Water <1 mg/mL Ethanol 96 mg/mL |
|---|---|
| 密度 | 1.55 |
| 折光率 | 1.49 |
| 沸点 | 470.55° C at 760 mmHg |
| 熔点 | 116-122°C |
| 分子量 | 481.300 g/mol |
| XLogP3 | 4.900 |
| 氢键供体数Hydrogen Bond Donor Count | 1 |
| 氢键受体数Hydrogen Bond Acceptor Count | 13 |
| 可旋转键计数Rotatable Bond Count | 5 |
| 精确质量Exact Mass | 481.039 Da |
| 单同位素质量Monoisotopic Mass | 481.039 Da |
| 拓扑极表面积Topological Polar Surface Area | 66.000 Ų |
| 重原子数Heavy Atom Count | 31 |
| 形式电荷Formal Charge | 0 |
| 复杂度Complexity | 684.000 |
| 同位素原子数Isotope Atom Count | 0 |
| 定义的原子立体中心计数Defined Atom Stereocenter Count | 0 |
| 未定义的原子立体中心计数Undefined Atom Stereocenter Count | 0 |
| 定义的键立体中心计数Defined Bond Stereocenter Count | 0 |
| 未定义的键立体中心计数Undefined Bond Stereocenter Count | 0 |
| 所有立体化学键的总数The total count of all stereochemical bonds | 0 |
| 共价键合单元计数Covalently-Bonded Unit Count | 1 |
| Purity(HPLC) | 98-100(%) |
|---|---|
| Appearance(T129709) | White Powder, Crystals and/or Chunks |
| Proton NMR spectrum | Conforms to Structure |
| LC-MS for identification | Conforms |
通过匹配包装上的批号来查找并下载产品的 COA,每批产品都进行了严格的验证,您可放心使用!
| 批号(Lot Number) | 证书类型 | 日期 | 货号 |
|---|---|---|---|
| 分析证书 | 24-02-21 | T129709 | |
| 分析证书 | 24-02-21 | T129709 | |
| 分析证书 | 24-02-21 | T129709 | |
| 分析证书 | 24-02-21 | T129709 | |
| 分析证书 | 24-02-21 | T129709 | |
| 分析证书 | 24-02-21 | T129709 | |
| 分析证书 | 24-02-21 | T129709 | |
| 分析证书 | 24-02-21 | T129709 | |
| 分析证书 | 24-02-21 | T129709 | |
| 分析证书 | 23-01-15 | T129709 |
¥385.90
| 1. Yan Zhu, Yanni Xu, Dong Han, Xiujin Zhang, Cheng Qin, Jing Liu, Lei Tian, Mengqi Xu, Yan Fang, Yang Zhang, Yabin Wang, Feng Cao. (2023) Scavenger receptor-AI targeted theranostic nanoparticles for regression of atherosclerotic plaques via ABCA1 modulation. Nanomedicine-Nanotechnology Biology and Medicine, 50 (102672). [PMID:37044196] [10.1016/j.nano.2023.102672] |
| 2. Yanyan Wang, Hai Gao, Xinya Huang, Zhaoan Chen, Pengyu Kang, Yunyi Zhou, Danhua Qin, Wenli Zhang, Jianping Liu. (2022) Cyclodextrin boostered-high density lipoprotein for antiatherosclerosis by regulating cholesterol efflux and efferocytosis. CARBOHYDRATE POLYMERS, 292 (119632). [PMID:35725197] [10.1016/j.carbpol.2022.119632] |
| 1. Han S, Zhuang H, Shumyak S, Wu J, Xie C, Li H, Yang LJ, Reeves WH. (2018) Liver X Receptor Agonist Therapy Prevents Diffuse Alveolar Hemorrhage in Murine Lupus by Repolarizing Macrophages.. Front Immunol, 9 (135). [PMID:29456535] |
| 2. Wang J, Xiao C, Wei Z, Wang Y, Zhang X, Fu Y. (2018) Activation of liver X receptors inhibit LPS-induced inflammatory response in primary bovine mammary epithelial cells.. Vet Immunol Immunopathol, 197 (87-92). [PMID:29475512] |
| 3. Zhang CJ et al.. (2021) Celastrol induces lipophagy via the LXRα/ABCA1 pathway in clear cell renal cell carcinoma.. Acta Pharmacol Sin, 42 (9): (1472-1485). [PMID:33303989] |
| 4. Wu D et al.. (2021) Dichlorodiphenyltrichloroethane Impairs Amyloid Beta Clearance by Decreasing Liver X Receptor a Expression.. Front Aging Neurosci, 13 (634948). [PMID:34045954] |
| 5. Yan Zhu, Yanni Xu, Dong Han, Xiujin Zhang, Cheng Qin, Jing Liu, Lei Tian, Mengqi Xu, Yan Fang, Yang Zhang, Yabin Wang, Feng Cao. (2023) Scavenger receptor-AI targeted theranostic nanoparticles for regression of atherosclerotic plaques via ABCA1 modulation. Nanomedicine-Nanotechnology Biology and Medicine, 50 (102672). [PMID:37044196] [10.1016/j.nano.2023.102672] |
| 6. Yanyan Wang, Hai Gao, Xinya Huang, Zhaoan Chen, Pengyu Kang, Yunyi Zhou, Danhua Qin, Wenli Zhang, Jianping Liu. (2022) Cyclodextrin boostered-high density lipoprotein for antiatherosclerosis by regulating cholesterol efflux and efferocytosis. CARBOHYDRATE POLYMERS, 292 (119632). [PMID:35725197] [10.1016/j.carbpol.2022.119632] |